Latest Shareholder Capital Raising News

Page 4 of 4
Alma Metals has announced a pro-rata non-renounceable rights offer to raise approximately $1.06 million, aiming to fund critical drilling and a scoping study at its Briggs Copper Project in Queensland.
Maxwell Dee
Maxwell Dee
26 May 2025
EBR Systems has raised A$55.9 million through a fully underwritten placement to fund the commercial rollout of its FDA-approved wireless cardiac pacing system, with plans for a limited market release in H2 2025 and expanded distribution in 2026.
Ada Torres
Ada Torres
22 May 2025
FFI Holdings has announced a $11 million non-renounceable entitlement offer priced at $3.50 per share, representing a notable discount to recent trading levels. The capital raise aims to fund property development and reduce debt, with directors backing the move by fully participating.
Eva Park
Eva Park
20 May 2025
HITIQ Limited has announced a non-renounceable entitlement offer to raise up to $2.92 million, supported by partial underwriting from GBA Capital and accompanied by new options issuance. The capital raise aims to fund expansion, product development, and operational growth.
Sophie Babbage
Sophie Babbage
15 May 2025
Terrain Minerals Ltd has announced a pro-rata entitlement offer to raise up to $1.82 million, supported by partial underwriting from directors Justin Virgin and Jason MacDonald. The capital raise aims to fund key exploration activities at the Smokebush Project and other initiatives.
Maxwell Dee
Maxwell Dee
12 May 2025
ReNu Energy has completed the sale of its hydrogen division and is set to acquire Janus Electric, a pioneer in electric truck battery swapping, backed by a substantial capital raise to scale operations.
Maxwell Dee
Maxwell Dee
30 Apr 2025
Infini Resources has successfully raised AUD$3.4 million through a flow-through share placement at a significant premium, positioning the company to aggressively advance exploration at its Portland Creek Uranium Project in Newfoundland.
Victor Sage
Victor Sage
6 Feb 2025
Percheron Therapeutics has terminated its phase IIb avicursen trial for Duchenne muscular dystrophy after failing to meet efficacy endpoints, while securing $14.85 million in fresh capital to explore new therapeutic opportunities.
Ada Torres
Ada Torres
31 Jan 2025